Lipocine announces lpcn 2101 abstracts accepted for presentation at aes 2025

Salt lake city , aug. 26, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that two abstracts related to lpcn 2101 have been accepted for poster presentation at the 2025 american epilepsy society (aes) annual meeting to be held december 5-9 in atlanta, georgia.  lpcn 2101 is in development for the potential treatment of epilepsy.
LPCN Ratings Summary
LPCN Quant Ranking